Page last updated: 2024-09-02

tamibarotene and gemcitabine

tamibarotene has been researched along with gemcitabine in 1 studies

Compound Research Comparison

Studies
(tamibarotene)
Trials
(tamibarotene)
Recent Studies (post-2010)
(tamibarotene)
Studies
(gemcitabine)
Trials
(gemcitabine)
Recent Studies (post-2010) (gemcitabine)
1981010512,5233,2086,923

Protein Interaction Comparison

ProteinTaxonomytamibarotene (IC50)gemcitabine (IC50)
Chain A, DEOXYNUCLEOSIDE KINASEDrosophila melanogaster (fruit fly)0.76
Equilibrative nucleoside transporter 1Homo sapiens (human)0.19

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Enomoto, A; Fujishiro, M; Iida, T; Imai, M; Ishikawa, T; Kawashima, H; Kinoshita, F; Kuwatsuka, Y; Mizutani, Y; Ohno, E; Shimizu, S; Tsuruta, T1

Trials

1 trial(s) available for tamibarotene and gemcitabine

ArticleYear
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
    BMC cancer, 2022, Feb-24, Volume: 22, Issue:1

    Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Repositioning; Female; Gemcitabine; Humans; Immunoglobulins; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tetrahydronaphthalenes; Treatment Outcome; Tumor Microenvironment; Young Adult

2022